Lota S. Zoth
Independent DirectorMs. Lota S. Zoth, C.P.A. is Independent Director of First Financial Bankshares, Inc. from April 2026. She serves as Independent Non-Executive Director of enGene Therapeutics Inc. (formerly known as enGene Holdings Inc.) since December 18, 2023. She has been Independent Director of 89bio, Inc. since August 2020. She served as Independent Director at Lumos Pharma, Inc. since November 2012. Ms. Zoth served as Lead Independent Director at Zymeworks Inc. since January 15, 2022 until December 7, 2023 and served as an Independent Chair of the Board of Directors since September 2019 until January 15, 2022. Ms. Zoth had been Director of Zymeworks Inc. since November 9, 2016 until December 7, 2023. She has been Director of Inovio Pharmaceuticals, Inc. since January 3, 2019. She served as a Director of Spark Therapeutics, Inc. from January 6, 2016 to December 17, 2019. Ms. Zoth served as the Chief Financial Officer and Senior Vice President of MedImmune, LLC from April 2004 to July 2007 and served as its Controller and Chief Accounting Officer from August 2002 to April 2004. Ms. Zoth served as an Acting Chief Financial Officer of MedImmune Inc., from January 8, 2004 to April 2004 and served as its Vice President until April 2004. She served on the Board of Directors for nonprofit Aeras from 2011 to 2018. At MedImmune, she was responsible for the day-to-day activities of the finance and accounting departments. At MedImmune, she was also responsible for oversight of treasury, risk management, information technology and corporate communications. Prior to joining MedImmune in August 2002, she served as Chief Financial Officer, Senior Vice President, Corporate Controller and Chief Accounting Officer of PSINet Liquidating, LLC. From 1998 to 2000, she served as Vice President, Corporate Controller and Chief Accounting Officer at Sodexho Marriott Services Inc. Prior to Sodexho Marriott, Ms. Zoth served as a Vice President, financial analysis of Marriott International, Inc.'s food and management services division. From 1991 to 1997, she held various positions of increasing responsibility in the PepsiCo, Inc. organization, including Assistant Controller of field services for Eastern Europe, Western Europe, the Middle East and North Africa for Pepsi-Cola International. From 1982 to 1991, she served as Auditor at of Ernst & Young. She served as Chair of Aeras. She had been Chair of the Board Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019) since July 27, 2018 and its Director since April 27, 2012 until 2019. Ms. Zoth served in financial executive roles Marriott International. She served as Independent Non-Executive Director of Circassia Pharmaceuticals Plc from February 9, 2015 to February 4, 2019. She has been an Independent Director of Ikaria Holdings Inc. since January 2008. She was a Director of Hyperion Therapeutics, Inc. from February 2008 to May 2015. She served as an Independent Director of Ikaria, Inc. from January 2008 to February 2014. She had been a Director of NewLink Genetics Corporation since November 02, 2012. In 2000, she was named Texas Tech's Distinguished Accounting Alumnus, an Annual award designated for outstanding contributions to the field of accounting. She is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in Accounting from Texas Tech University in 1982, graduating summa cum laude.
Positions
- Company NameInovio Pharmaceuticals, Inc.Stock CodeINOPositionIndependent DirectorColleagues
- JEJacqueline E. SheaCEO, President & Director
- SXSimon X. BenitoIndependent Chairman of Board of Directors
- PDPeter D. KiesChief Financial Officer
- MSMichael SumnerChief Medical Officer & Head of Development
- LMLaurent M. HumeauChief Scientific Officer & Chairman of the Scientific Advisory Board
- RLRobert L. CrottyGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- WLWendy L. YarnoIndependent Director
- LSLota S. ZothIndependent Director
- Company NameenGene Therapeutics Inc.Stock CodeENGNPositionIndependent Non-Executive DirectorRelated SecuritiesColleagues
- RHRonald H. W. CooperPresident, CEO & Director
- MTMichael Thomas HeffernanIndependent Non-Executive Chairman
- KRKathleen RichtonSenior VP of Finance, Principal Accounting & Financial Officer and Controller
- JCJoan ConnollyChief Technology Officer
- JGJason G. DuncanChief Legal & Administrative Officer
- LSLauren Stival HopferExecutive Director of Investor Relations
- PDPaul D. RobbinsChairman of Scientific Advisory Board
- WSWouter Sebastian Johannes JoustraIndependent Non-Executive Director
